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1. Introduction
The global prevalence of diabetes was estimated at 285 million in 2010.[1] The countries with
the most significant number of sufferers in 2010 were India, China, United States, Russia and
Brazil.[1] Countries with a low and middle income experience the worst burden of diabetes,
compared with higher income countries.[1]
The total prevalence of diabetes in children and adults in the United States was 25.8 million in
2011, which is 8.3% of the entire population.[2] It is estimated that 18.8 million of this figure
are diagnosed and 7 million remain undiagnosed.[2] 79 million individuals in the United States
are expected to be at risk of diabetes.[2] The overall cost of diabetes in the United States in 2012
was $245 billion, with $176 being directly related to medical costs and $69 billion related to
reduced productivity.[2] In the UK, 2.6 million individuals were diagnosed with diabetes in
2009,[3] and this is expected to exceed 4 million in 2024.[4] It is also expected that up to 500,000
other UK individuals remain undiagnosed.[5] An estimated one in 20 individuals in England
have diabetes-both diagnosed and undiagnosed, and this is marginally reduced UK-wide.[1]
For adults in the UK it is estimated that 10% of individuals with diabetes mellitus (DM) have
Type 1 diabetes mellitus and 90% have type 2 diabetes mellitus.[1, 6]
Effective management of diabetes reduces complication risk.[7] However failure to control the
condition can lead to microvascular and macrovascular complications. At the time of diagno‐
sis, 50% of those with type 2 diabetes mellitus face complications.[8] Complications may begin
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five to six years prior to diagnosis, whilst the onset of diabetes itself may precede the clinical
diagnosis by a decade.[9]
Diabetic retinopathy (DR) is the most frequent complication associated with diabetes mellitus,
and is the number one cause of blindness in individuals of working age in developed nations.
[10] Indeed individuals with diabetes are 10 to 20 times at greater risk of developing blindness
than those without the diagnosis.[11] DR prevalence in the Wisconsin Epidemiological Study
of Diabetic Retinopathy (WESDR) was identified as 50.1% and 54.2% in the diabetes control
and complications trial (DCCT) in insulin-dependent diabetes mellitus (IDDM)[12, 13] DR
prevalence in non-insulin dependent diabetes mellitus (NIDDM) was found to be 35-39% in
the United Kingdom Prospective Diabetes Study.[14] During 2005-2008, 4.2 million (28.5%) of
diabetics in the United States aged 40 years and above suffered from diabetic retinopathy, with
0.7 million (4.4% of these diabetics) experiencing advanced DR, thus risking severe loss of
vision.[2] In the WESDR, 1.4% of patients with IDDM were able to achieve a best-corrected
visual acuity of 20/80 to 20/160, with 3.6% having an acuity of 20/200 or worse in the better eye.
[15] 3% of the older-onset group had vision ranging from 20/80 to 20/160, and 1.6% were 20/200
or worse in the best eye.[15]
1.1. Incidence of visual impairment
10 years following diabetes mellitus (DM) onset, blindness (a visual acuity of equal to or worse
than 20/200 in the best eye) was 1.8% in the type 1 cohort, 4.0% in the insulin-treated type 2
group and 4.8% in the non-insulin-treated type 2 patients.[16] Further, in these groups the
incidence of visual impairment at 10 years (loss of 15 letters on a 0-70 letter scale) was identified
as 9.4, 37.2 and 23.9 respectively.[16]
There appear to be few paediatric cases of DR, though it has been identified in children as
young as 5.5 years in an American study, and severe blindness has also been described in
adolescents as the microvascular effects of diabetes, including DR, can develop during puberty
years.[17]
1.2. Historical developments
The Diabetic Retinopathy Study in the 1970s and the Early Treatment Diabetic Retinopathy
Study in the 1980s, identified the major effects of retinal photocoagulation on visual loss
associated with proliferative diabetic retinopathy and macular oedema, as well as influencing
guideline and screening programme development for early identification and management of
diabetic retinopathy.[18, 19, 20] Following this, both the incidence and progression risk of
diabetic retinopathy has reduced from an estimated 90% of patients with diabetes, to less than
50%.[20] In the WESDR, which focused on individuals with type 1 diabetes mellitus, the yearly
incidence of proliferative diabetic retinopathy reduced by 77% from 1980 to 2007, with a 57%
reduction in visual impairment during this same time period.[21] Evidence from a range of
international studies, including those from Sweden, Denmark and the United States, indicate
that individuals recently diagnosed with type 1 or type 2 diabetes mellitus have a significantly
reduced risk of proliferative diabetic retinopathy, macular oedema and visual impairment,
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compared with those diagnosed in the past.[22, 23, 24, 25, 26] The considerable decrease in the
prevalence and incidence of diabetic retinopathy and visual impairment over the previous few
decades suggests improved glycaemic, blood pressure and lipid level management.[26]
1.3. A global epidemic
However the number of individuals with diabetes is expected to exponentially increase
internationally to 429 million by 2030, attributed to the increased prevalence of obesity, an
ageing population and enhanced identification of the disease.[27, 28] This represents a major
public health concern. As an exemplar, in India 32 million individuals were diagnosed with
diabetes in 2000 and an estimated 79 million will be affected by 2030, and if complication
prevalence remains the same, around 0.7 million Indians will suffer from proliferative diabetic
retinopathy and 1.8 million with have macular oedema with clinical manifestations.[29] This
identifies a large population at risk of visual impairment attributed to their diabetes, and
highlights the importance of effective epidemiological surveillance of developing countries as
there may be reduced delivery of health care capacity compared with developed nations.[20]
2. Pathophysiology
The DCCT and United Kingdom Prospective Diabetes Study (UKPDS) both support the
significant association between a long-term hyperglycaemic status and the establishment, as
well as progression, of DR.[36, 37] However the mechanism which result in microvascular
injury attributed to hyperglycaemia is uncertain.[36, 37] Several interlinking molecular
pathways have been discussed as being possibly involved in the mechanism, and these include
enhanced polyol pathway activity, diacylglycerol-(DAG-)PKC pathway activation, enhanced
growth factor expression for example vascular endothelial growth factor (VEGF) and insulin-
like growth factor-1 (IGF-1), haemodynamic alterations, faster advanced glycation endprod‐
ucts (AGEs) production, oxidative stress, renin-angiotensin-aldosterone system (RAAS)
activation, inflammation and leukostasis.[38] However the final metabolic pathway resulting
in the establishment of DR is uncertain.[39]
2.1. Polyol pathway
The polyol pathway is involved in the metabolism of surplus glucose.[38]
Aldose reductase (AR), which exists in the retina, is involved in the reduction of glucose into
sorbitol, employing nicotinamide adenine dinucleotide phosphate (NADPH) as a cofactor.[38]
Sorbitol is then converted to fructose using sorbital dehydrogenase (SDH).[38] Sorbitol is
impermeable to cellular membranes, and therefore there is an intracellular accumulation of it,
which is followed by the gradual metabolism of sorbitol to fructose.[40] NADPH is also
employed as a cofactor for glutathione reductase in the regeneration of intracellular gluta‐
thione, therefore limiting the antioxidant capability of the cells.[38]
Sorbitol accumulation may have multi-injurious effects on retinal cells, such as osmotic injury.
[41] Further, the fructose formed in the polyol pathway can undergo a phosphorylation
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reaction, forming fructose-3-phosphate, with the potential for further degradation to 3-
deoxyglucosone.[42] Both of these products are potent glycating mediators and can support
the production of AGEs.[42] Moreover employment of NADPH in the polyol pathway, reduces
NADPH availability for glutathione reductase, thereby preventing the production of reduced
glutathione, resulting in reduced protection against oxidative stress.[43]
More recently, evidence suggests that AR is localised in retinal cells such as pericytes,[44]
retinal endothelial cells,[45] ganglion cells,[45] Muller cells,[45] retinal pigment epithelial cells
and neurons.[45, 46] Enhanced AR activity may be involved in retinal cell destruction.[43]
Importantly, pericyte or endothelial cell exposure to enhanced concentrations of glucose or
galactose reduces the survivability of these cells,[38] with reversal of this cell death on the
administration of ARIs.[47] Generally, electrolye imbalance attributed to high aldose reductase
levels results in cellular death, in particular retinal pericytes, which contribute to microaneur‐
ysm formation.[48]
The polyol pathway is also associated with other pathophysiological characteristics in DR,
including a thickened retinal capillary basement membrane,[49] with ARI preventing this
thickening in rat models.[50] ARIs are also effective in reducing leukocyte adhesion in
endothelial cells,[51] which results in leukostasis and is discussed later, as well as preventing
enhanced vascular permeability and blood retinal barrier breakdown which is a hallmark
feature of DR.[46] Genetically, AR may also contribute to DR establishment.[52]
Thus far, ARIs employed in animal models at the onset of diabetes has been useful in pre‐
venting DR, though limited clinical benefit has been shown.[38]
2.2. Protein glycation
The establishment and accumulation of AGEs is a significant contributor to DR.[53] AGEs are
molecules produced non-enzymatically when sugars are reduced with free amino groups of
proteins, lipids and nucleic acids.[38] Normally, AGEs are produced at a constant and gradual
Figure 1. Polyol pathway
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rate, commencing at the embryonic stage and accumulating with time.[38] In the context of
increased glucose availability in diabetes, their production is accelerated.[54]
AGEs are important in several diabetic complications.[38] For example, they have been
identified in the retinal vessels of diabetics, and these AGE levels have been correlated with
those found in the serum, as well as retinopathy severity.[55] AGE interaction with certain cell
surface receptors such as RAGE, CD36 and the macrophage scavenger receptor have been
described in DR development.[55]
Animal studies suggest significantly high AGE exposure is contributory to renal and vascular
complications.[56, 57] In rats which developed diabetes, retinal capillaries had enhanced AGE
accumulation, as well as a loss of pericytes.[53] Treatment with AGE formation inhibitors
considerably reduced AGE accumulation, and stopped microaneurysm formation, acellular
capillaries and pericyte loss.[53] In another study, rats with a diabetes duration of 29 weeks,
there was an increase in acellular capillaries by more than three times compared to previously,
and there was increased thickening of the basement membrane.[56] A thickened capillary
basement membrane and enhanced deposition of extracellular matrix components is a
contributor to the development of abnormal retinal haemodynamics.[58] Again, treatment
with an AGE formation inhibitor prevented capillary dropout and reduced basement mem‐
brane protein formation.[56]
These studies, which are still in their infancy, identify AGE formation and activation of their
respective receptors as important targets for pharmacotherapeutic strategies.[38]
2.3. Activation of Protein Kinase C (PKC)
PKC is a kinase involved in signal transduction activity in response to a stimulus which may
be hormonal, neuronal or growth factor in origin.[38] The Beta1/2 isoform of PKC is associated
with DR development.[59] Raised blood glucose increases glucose flux in the glycolysis
pathway, thereby increasing diacylglycerol (DAG) production. DAG is a major PKC activator.
[60] Clinical and experimental research has identified an increase in DAG and PKC activation
in diabetes.[59]
PKC can also influence other physiological pathways therefore having the capability to alter
endothelial permeability, retinal haemodynamics and expression of vascular endothelial
growth factor (VEGF) in the retina and enhanced leukostasis.[59, 61, 62]
In particular, the expression of the PKC beta1/2 isoform is increased in diabetics, thereby
contributing to DR pathogenesis by extracellular matrix (ECM) protein synthesis, remodeling
of the ECM, increased angiogenic factor production, endothelial and leukocyte cell abnormal‐
ities, ultimately resulting in occluded capillaries and leukostasis, with alterations in retinal
blood flow.[38] The PKC pathway also influences other activities such as inflammatory
changes, neovascularisation and abberant haemodynamics.[38] This further progresses the
pathogenic changes in DR. Experimentally, PKC-beta1/2 inhibitors significantly reduce DR
progression.[63] In clinical trials, inhibitors do not prevent DR but considerably reduce the
associated vision loss.[64]
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2.4. Haemodynamic alterations
Hypertension, which has a high incidence in diabetes, is likely to contribute to DR progression.
[38] This may involve the mechanical stretch and sheer stresses associated with hypertension,
injuring endothelial cells. Enhanced retinal perfusion and increased blood viscosity can also
lead to endothelial dysfunction.[65] Further, the endocrine mechanisms which have regulatory
influences over blood pressure are also independently involved in DR pathogenesis.[66]
2.5. Renin-angiotensin-aldosterone system involvement
RAAS is fundamental in blood pressure and fluid regulation, with aberrant changes identified
in this system in diabetics.[66] There is an increase in the expression of certain receptors and
signaling molecules in the retina, in PDR, including renin, angiotensin converting enzymes
(ACE) and angiotensin receptors.[66, 67] This is independent of systemic blood pressure.[38]
In experimental studies, ACE inhibitor use prevents neovascularization and several clinical
studies suggest that targeting of RAAS reduces the incidence of retinopathy in type 1 diabetes
and prevents progression of DR.[68]-[70]
The exact mechanism of RAAS involvement in DR is uncertain, though in vitro evidence
identifies association with PKC activation and VEGF signaling.[71]
2.6. Inflammatory changes and Leukostasis
The importance of inflammation, in particular subclinical inflammation in DR development is
considerable, though complex.[38] The hyperglycaemic state, oxidative stress, AGE produc‐
tion and hypertension are all contributory to the inflammation. Moreover, the inflammation
is self-propagating by means of cytokines, adhesion molecules, VEGF activity, increased RAGE
expression, nitric oxide regulatory changes and NF-kB signaling.[38] This subclinical retinal
inflammation increases intraocular blood pressure by the involvement of endothelial nitric
oxide synthase (eNOS), formation of new but weak vessels and their enhanced VEGF perme‐
ability which results in retinal haemorrhages, as well as leukostasis attributed to multiple
proinflammatory agents.[38] Leukostasis is crucial in DR pathogenesis, resulting in capillary
occlusion, reactive oxygen species (ROS)-related cellular death and local retinal amplification
of the inflammatory activities.[72]-[75]
There is a considerable increase in systemic proinflammatory cytokine expression, soluble and
cell surface adhesion molecule activation and chemokine expression in the DR retina.[76] The
increase in serum proinflammatory cytokines, adhesion agents and immune cell activation in
diabetes correlates with DR progression.[77, 78] Endothelial abnormalities, as well as increased
proinflammatory cytokines and adhesion molecules, contribute to leukostasis by increasing
leukocyte and endothelial cell interaction.[79, 80] Localised inflammation including the
activation of microglia, macrophages and immune cells is considered important in DR
pathogenesis.[81] This is corroborated by the use of minocycline, an antibiotic and anti-
inflammatory agent, which prevents microglial activation and thereby prevents DR.[81]
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2.7. Oxidative stress
Oxidative stress occurs when the level of ROS or oxygen radicals increase to a degree where
the antioxidant defences are unable to cope.[82] Oxidative stress established by hyperglycae‐
mia is pivotal in microvascular complications.[83] Correlation between hyperglycaemia,
alterations in redox homeostasis and oxidative stress is essential in DR pathogenesis.[84, 85]
Increased ROS are likely to be involved in both the development and progression of DR.[86]
It has been proposed that oxidative stress may be a “unifying mechanism” linking several
injurious pathways induced by the hyperglycaemic state in DR.[87] ROS derived from
mitochondria cause DNA breaks, which activate poly-(ADP-ribose)-polymerase (PARP).[87]
PARP activation results in inhibition of glyceraldehyde phosphate dehydrogenase (GAPDH)
activity, causing glycolytic metabolite accumulation.[87] These metabolites cause the activa‐
tion of AGE, PKC-beta-2, polyol and hexosamine pathways.[87] NADPH oxidase-derived ROS
may also be involved in the pathogenesis.[87]
2.8. Growth factor involvement
The importance of growth factors in DR is confirmed by the rare observation of serious DR in
growth hormone deficient diabetic dwarfs,[88] and this is further corroborated by slowed DR
progression in individuals with pituitary ablation in the 1970s.[89]
The growth factor most frequently considered in DR is VEGF, which promotes angiogenesis,
causes blood-retinal barrier breakdown, endothelial cell growth stimulation and neovascula‐
rization, as well as increased vascular permeability in an ischaemic retina.[90]-[92] Ischaemia
in the retina causes angiogenic factors, such as vascular endothelial growth factor (VEGF) to
establish neovascularization, resulting in proliferative diabetic retinopathy (PDR). VEGFs are
produced by retinal pigment epithelium, pericytes and retinal endothelial cells.[39] Animal
and clinical evidence suggests VEGF, especially the 165 isoform, is important in the develop‐
ment and progression of DR.[93, 94]
Anti-VEGF agents have clinical efficacy in the treatment of DMO, but are not effective in all
patients.[38] Further long-term use of anti-VEGF agents should be considered with caution in
DR.[38]
2.9. Carbonic Anhydrase (CA)
Enhanced intraocular VEGF concentrations correlates with increased vascular permeability,
contributing to haemorrhage, exudate formation, vascular leakage, and ultimately leading to
NPDR, angiogenesis and vasculogenesis leading to PDR.[38]
CAs are ubiquitous metalloenzymes which cause conversion of carbon dioxide to bicarbonate
and protons.[38] Diabetics have considerably higher CA concentrations than controls,[95] and
CA inhibitors reduce DR progression and prevents visual loss in animal and clinical research.
[96] The mechanisms involved may include reduced humour secretion, induction of vasodi‐
latation and improved ocular blood flow, platelet aggregation inhibition and reduction in
vascular permeability.[95]
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2.10. Neurodegeneration in the retina
As well as the changes already described, structural and functional alterations can injure
certain non-vascular cells.[38] It is believed that neurodegeneration of retinal neurons and glia
may even precede microaneurysm development.[97]
3. Risk factors
Epidemiologic studies have shown several risk factors associated with the incidence of diabetic
retinopathy and subsequent macular oedema (table 1). Several other risk factors have also been
implicated in disease progression such as sleep apnoea [98], non-alcoholic fatty liver disease,
genetic mutations[21, 99] and serum prolactin, homocysteine and adinopectin levels [33, 31,
34]. However the exact contribution of these factors to disease progression remains unknown.
The precise association of smoking with diabetic retinopathy appears complex and is unclear.
Type of diabetes
Duration of diabetes
Poor glycaemic control
Hyperlipidaemia
Hypertension
Pregnancy
Table 1. Recognised risk factors associated with diabetic retinopathy
3.1. Type of diabetes
Type 1 diabetic patients are at substantially higher risk than type 2, which is independent of
the duration of the disease process[100, 101]. Both severity and prevalence increase with age
in the former group but not the later.
3.2. Duration of diabetes
A clear correlation exists between diabetic retinopathy and disease duration[ 1]. This risk factor
has influenced the formation of guidelines for early examination of suspected patients to
decrease disease progression. In two studies [100, 102] evidence was shown that after 15 years
retinopathy would be present in virtually all type 1 diabetics and up to 75% of type 2 diabetics,
with 2% becoming blind and up to 10% developing severe visual impairment. Puberty is now
an accepted risk factor for retinopathy in type 1 diabetes, due to the acceleration of microvas‐
cular compromise as a result of physiological changes post puberty [103]. One study found
that younger post-menarchal subjects were up to 3.2 times more likely to develop retinopathy,
in comparison to pre-menarchal subjects[104]. Subjects older than 13 years at the time of
diagnosis were more likely to suffer from retinopathy, than those younger. A four year follow-
Ophthalmology - Current Clinical and Research Updates256
up also showed that the same post-menarchal had greater progression of their retinopathy
than pre-menarchal (P=0.06). While the exact mechanism is not known, hormonal factors have
been speculated to play a part.
3.3. Glycaemic control
The relationship between glycaemic control and onset/progression of diabetic retinopathy is
well documented. Intensive metabolic control has shown a decreased in diabetic related
complications [105]. Studies such as the Early Treatment of Diabetic Retinopathy Study
(ETDRS) and Diabetes Control and Complication Trial (DCCT)[13] show that risk of progres‐
sion is reduced with aggressive glycaemic control. Glycosylated haemoglobin levels have
shown a relationship with the severity of proliferative diabetic retinopathy[106]. However,
while glycosylated haemoglobin remains a formidable risk factor, it only accounted for 11%
of all risks for retinopathy in DCCT [107].
3.4. Hyperlipidaemia
Association of hyperlipidaemia and diabetes is well documented [108]. A statistically signifi‐
cant association between elevated serum total cholesterol and low density lipoprotein
cholesterol and the severity of retinal hard exudation in patients with diabetic retinopathy was
confirmed by the ETDRS group and the Wisconsin Epidemiologic Study of Diabetic Retinop‐
athy (WESDR) found [109]. As reported by Chew found patients with serum cholesterol level
more than 240mg/dl were twice as likely to have more hard exudates as those patients with
serum cholesterol level 200 mg/dl [110].
3.5. Hypertension
A major risk factor of cardiovascular disease in diabetics is hypertension. An age-adjust‐
ed 82% increase in risk of diabetes-related death is thought to come from this risk factor
alone.[111] This is accorded with the theory that increased blood pressure is implicated in
the onset of diabetic retinopathy [112, 113]. The UK Prospective Diabetic Study (UKPDS)
showed that  tight  blood pressure  control  (144/82  vs  155/87)  was  associated with  a  34%
reduction in retinopathy with a 47% reduction in deterioration of  visual  acuity of  three
lines  [14].  The  use  of  angiotensin-converting-enzyme (ACE)  inhibitors  and  their  role  in
directly affecting the progression of retinopathy (as opposed to their therapeutic effects in
hypertension) was the subject of much debate. ACE inhibitors were found to be associat‐
ed  with  reduced  levels  of  vascular  endothelial  growth  factor  in  diabetic  retinopathy
patients[114]. However in the UKDPS group demonstrated an overall reduction of blood
pressure was proven to be effective in slowing down the progression of retinopathy, rather
than the type of antihypertensive drug used [115]. More recently, the ‘DIabetic REtinop‐
athy Candesartan Trial’ (DIRECT) study recently posited that while candesartan did not
have any beneficial effect on the progression of retinopathy in type 1 diabetic patients, it
did yield improvement in type 2 patients with mild to moderate retinopathy [69, 68].
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3.6. Pregnancy
Many studies have concluded that diabetic women in pregnancy have a substantial risk of
worsening their retinopathy [116, 117] although resolution of ocular changes in post-partum
period is reported [116, 118]. Studies by Phelps et al [119] and the Diabetes in Early Pregnancy
Study (DIEP) group [120] concluded that retinopathy was most likely to progress in those who
had the poorest control at baseline. DIEP also found that a disease duration of more than 15
years and severity of existing retinopathy were the most important factors in the development
and progression of retinopathy in pregnancy. Type 1 diabetic women are most at risk and
should be undergo an ophthalmic examination prior to pregnancy and counselled on good
glycaemic control. The exact mechanism of progressive retinopathy in pregnant diabetic
woman is the subject of much debate. Factors thought to be involved include duration of
diabetes, co-existing hypertension, poor glycaemic control and its rapid normalisation during
pregnancy [121].
4. Signs
Microaneurysms are out-pouchings of the capillary wall that form by either focal dilatation of
the capillary wall in the absence of pericytes, or fusion of the two arms of a capillary loop.
Clinically these are seen as tiny red dots. Retinal haemorrhages are divided into intraretinal,
retinal nerve fibre layer and deeper dark round haemorrhages. Intraretinal haemorrhages are
located in the middle layers of the retina and give rise to dot/blot configuration. Retinal nerve
fibre layer haemorrhages are flame-shaped and arise from larger superficial pre-capillary
arterioles. Deeper dark round haemorrhages represent retinal infarcts within the middle layers
and are marker for progression to retinal neovascularisation. Cotton wool spots result from
nerve fibre layer infarcts. Axon disruption causes accumulation of neuronal debris in the nerve
fibre layer. Clinically these are seen as small fluffy lesions that can obscure underlying blood
vessels. Exudates are composed of lipoprotein and lipid-filled macrophages located within the
outerplexiform layer. They are seen as waxy yellow lesions with relatively distinct margins.
They tend to progress as retinopathy worsens and can affect the macula resulting in macular
oedema. Exudates reabsorb spontaneously when leakage ceases over a period of months.
Venous changes include beading of blood vessels, tortuosity, and focal narrowing with
dilatation called ‘beading’. The extent of venous change correlates well with the proliferative
change. IRMA, or intraretinal microvascular abnormalities are arteriolar venous shunts that
run from retinal arterioles to venules. They bypass capillary beds and are seen in areas of
capillary hypoperfusion. Arteriolar narrowing often can be marker for ischaemic dysfunction.
Proliferative retinopathy is seen as new preretinal vessels that may arise at the optic disc or
elsewhere in the retina or iris. There are fine fragile vessels that can develop fibrous tissue over
time.
Diabetic macula oedema is one of or a combination of focal, diffuse or ischaemia. It is the main
reason for visual impairment and represents foveal oedema, exudates or ischaemia. Focal
maculopathy has retinal thickening and exudates. Fluoroscein angiogram shows late focal
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hypofluorescence from leakage. Diffuse maculopathy can be associated with cystoids changes
and diffuse retinal thickening. Fluoroscein angiogram shows late hypofluorescence with a
flower petal pattern if cystoids macula oedema is present. Ischaemic maculopathy often has a
relatively normal looking macula in the presence of reduced visual acuity. Fluoroscein
angiogram shows non-perfusion and an enlarged foveal avascular zone.
Figure 2. Microaneurysms at the macular and blot haemorrhages temporally
Figure 3. Exudates and microaneurysms at the macula, blot haemorrhages at the arcades, new vessels on the disc and
cotton wool spots, IRMA and venous beading supoertemporally.
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Figure 4. New vessels on disc and elsewhere inferotemporally
5. Classification
Diabetic retinopathy classification is based on who is classifying the disease. One approach
has been for screening and one is based on grading severity in the context of ophthalmic signs.
There are different screening systems in different parts of the developed world. In the UK, the
English National Screening Criteria[122] is used to merit ophthalmological referral, seen in the
table below. Two commonly used classification systems for classification in the context of
ophthalmic signs are the Airlie House Classification [123] and the international (AAO)
classification [124]. There are similarities and overlap in both. For the purpose of this chapter
we will focus on the Airlie House classification.
The Airlie House classification was the original classification that has subsequently undergone
modification in the Early Treatment of Diabetic Retinopathy Study (EDTRS)[125] aimed at
grading retinopathy in the context of ophthalmic signs. EDTRS was first developed in 1997,
but has undergone change and development for countries without significant screening and
programmes and for the purpose of research. The sight threatening risk of diabetic retinopathy
was incorporated into the later clinical grading system. Broadly this incorporates low risk non-
proliferative retinopathy (3 substages), severe non-proliferative diabetic retinopathy, prolif‐
erative retinopathy and the presence of macula oedema.
Below is based on the Airlie House classification:
Mild Nonproliferative Diabetic Retinopathy (NPDR): At least one microaneurysm
Moderate NPDR: Severe retinal haemorrhages in at least one quadrant, cotton wool spots,
venous beading or IRMA.
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Severe NPDR: Severe retinal haemorrhages in four quadrants or venous beading in two
quadrants; or extensive IRMA in one quadrant
Proliferative diabetic retinopathy: based on location and risk
Location: new vessels at disc (NVD) or elsewhere (NVE)
Risk: Low risk where neovascularisation of the optic disc is less than one-quarter to a third of
the disc area with no vitreous haemorrhage.
High risk: mild NVD with vitreous haemorrhage.
Moderate to severe NVD (one quarter to a third disc areas)
New vessels elsewhere more than one half disc areas with vitreous haemorrhage.
ENSC Grade Features
Retinopathy
grade
R0 No retinopathy
R1 Retinal microaneurysms, haemorrhages and or exudates not within the definition of maculopathy
R2 (Pre-proliferative) venous beading, venous loop or IRMA, dot or blot haemorrhages and cotton
wool spots
R3 Proliferative: NVD, NVE or pre-retinal or vitreous haemorrhage, pre-retinal fibrosis and tractional
retinal detachment
M0 No maculopathy
M1 Exudate within 1 disc diameter of fovea centre, or circinate exudates within the macula, or retinal
thickening within 1 disc of fovea centre only if associated with vision of 6/12 or worse
P Focal/grid laser to macula or peripheral scatter
U Unobtainable
Table 2. The English National Screenin Committee Guidelines
Maculopathy
Focal: Well circumscribed areas of leakage with oedema and exudates, that may surround
microaneurysms
Diffuse: Generalised leaking with oedema
Ischaemic: Reduced visual acuity with relatively normal clinical appearance but macula
ischaemia on FFA.
Mixed: A combination of the above
Clinical significant macula oedema (CSMO)
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• Retinal thickening at or within 500μm of the centre of the macula
• Hard exudates at or within 500μ of the centre of the macula if associated with adjacent retinal
thickening
• Retinal thickening of > 1 disc area any part of which is within one disc diameter of the centre
of the macula.
More recently the terms centre involving and non-centre involving macula oedema have been
used.
6. Investigations
Diabetes Mellitus is a complex disease requiring a multidisciplinary approach. The systemic
investigations requested for a patient identified with ocular manifestations of the disease may
provide valuable information regarding other organ systems affected which are not yet
clinically apparent. Some of the general investigations below may be requested by an oph‐
thalmologist depending on the local health setting but require referral for result interpretation
and subsequent management by diabetologist colleagues.
6.1. Systemic Investigations
6.1.1. HbA1C
The Diabetes Control and Complication Trial (DCCT) [126] and subsequent follow-up study,
Epidemiology of Diabetes Interventions and Complications (EDIC), highlighted that the effect
of good glycaemic control on progression of retinopathy is significant and persists for at least
10 years. Due to the 8-12 week turnover of erythrocytes the glycosylated haemoglobin molecule
is a more useful marker of glucose control than a random blood glucose measurement.
6.1.2. Lipids
Recent studies [127] have identified the importance of cholesterol lowering medications to both
treatment naïve and previously treated hypercholestrolaemic type 2 diabetics in reducing the
risk of clinically significant macular edema (CSME), and diabetic retinopathy progression[127,
128]. Fasting lipids should therefore be requested in new patients.
6.1.3. Urea & electrolytes
Diabetic nephropathy is an important consequence of microvascular disease and all patients
should be screened for any renal dysfunction.
6.1.4. Genetic markers
Various clinical studies have looked at retinopathy clusters in families with type 1 diabetes.
Genetic studies have analysed risk genes for retinopathy [The Diabetes Control and Compli‐
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cations Trial Research Group, 1997][126]. No study has provided an evidence base for genetic
testing in diabetic patients to predict the rate of retinopathy progression and therefore genetic
testing is not currently recommended for routine practice.
6.1.5. Blood pressure
Patients should be referred to a physician for investigation of all modifiable risk factors
including blood pressure and smoking cessation, both known to contribute to the rate of
diabetic retinopathy progression. [Gaede et al. 2008][129].
7. Imaging
7.1. Fundus Photography
Fundus photography provides a useful photographic record of the posterior pole and is useful
in the Diabetic Screening Programme, but relies on 2-dimensional surrogate markers of
macular thickening since it cannot quantify actual thickening.
7.2. Optical Coherence Tomography (OCT)
Optical Coherence Tomography is a non-invasive imaging technique which is non-contact and
facilitates high resolution cross-sectional imaging of the anterior segment, vitreous, retina and
optic nerve head. Rather than the sound waves of B-scan ultrasonography, OCT uses light
interferometry (near-infrared) to interpret the interference patterns of wave superposition.
OCT is useful is very sensitive in detecting change in macula thickness and therefore useful in
the diagnosis of diabetic macula oedema. It is also able to identify the loss of ganglion cells in
the retina, which precedes vascular changes. Because OCT gives a quantitative measure of
retinal thickness it is critical in monitoring retinal thickness in response to treatment e.g.
Macula laser or Anti-VEGF agents.
Different tissue reflectivities are depicted by different colours; red denotes high reflectivity,
green-yellow intermediate reflectivity and blue-black low reflectivity. In addition to numerical
measures of retinal thickness a topographical map is created which is colour coded according
to thickness.
7.3. Fundus Fluorescein Angiography (FFA)
Fundus Fluorescein Angiography involves the injection of an orange water-soluble dye;
sodium fluorescein into the systemic circulation. It remains predominantly intravascular and
is fluorescent; i.e. it emits light of a longer wavelength when stimulated by light of a lower
wavelength. After intravenous injection, fundus photography is performed in a rapid se‐
quence. Blue filtered light is absorbed by the molecule as it enters the retinal circulation and
in turn emits yellow-green light.
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The FFA image maps the retinal vasculature and the structural and functional integrity of the
vessels.
Figure 5. a. Fundus photograph of Diabetic Maculopathy (Circinate hard exudates, haemorrhages) b. Optical Coher‐
ence Tomography of Diabetic Maculopathy (Intraretinal cystic thickening) c. Fundus Fluorescein Angiogram of Diabet‐
ic Maculopathy
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Normally 10-15 seconds elapse between dye injection and arrival of the dye in the short ciliary
arteries. Choroidal circulation precedes retinal circulation by 1 second. Transit of dye through
the retinal circulation takes approximately 15 to 20 seconds.
Figure 6. a. Fundus Photograph of New Vessel at Disc (NVD). Note PRP laser scars b. Fundus Fluorescein Angiogram of
New Vessel at Disc (NVD) with evidence of peripheral ischaemia
The normal angiogram can be divided into five phases
1. Choroidal phase: The choroid is filled by the short ciliary arteries resulting in initial
patching filling of lobules, quickly followed by a diffuse blush as dye leaks out of the
choroidocapillaris.
2. Arterial phase: The central retinal artery fills about 1 second after choroidal filling
3. Capillary phase: The capillaries quickly fill following the arterial phase. The perifoveal
capillary network is particularly prominent, as the underlying choroidal circulation is
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masked by luteal pigment in the retina and melanin pigment in theretinal pigment
epithelium (RPE). At the centre of this capillary ring is the foveal avascular zone 500um
in diameter.
4. Venous phase: Early filling of the veins is from tributaries joining their margins, resulting
in a tramline effect. Later the whole diameter of the veins is filled.
5. Late (recirculation) phase: 10 to 15 minutes later only a little dye remains within the blood
circulation. Dye which has left the blood to ocular structures is particularly visible during
this phase.
Below images are taken from clinical practice for common diabetic pathology (Images kindly
provided by Mr Jignesh Patel, Essex County Hospital, Colchester).
Figure 7. a. Fundus Photograph of New Vessels Elsewhere (NVE). b. Fundus Fluorescein Angiogram of New Vessels
Elsewhere (NVE)
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Figure 8. a. Fundus Photograph demonstrating PRP laser burns b. Fundus Fluorescein Angiogram of the above pa‐
tient showing laser scars
8. Management of diabetic retinopathy
The management of diabetic retinopathy involves a multidisciplinary approach with involve‐
ment of the ophthalmologist, physician and dietician. The underlying diabetes and risk factors
should be managed concurrently with the ocular complications of diabetes.
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8.1. Medical management
8.1.1. Blood glucose control
Tight glycaemic control reduces the incidence and progression of diabetic retinopathy. The
Diabetes Control and Complications Trial (DCCT)[131] showed that in type 1 diabetics
effective glycaemic control reduced the incidence of diabetic retinopathy by 76% and progres‐
sion of diabetic retinopathy by 54%. Similarly the United Kingdom Prospective Diabetes Study
(UKPDS)[132] reported reduced microvascular complication, by 25% and the need for laser
photocoagulation by 29% in type 2 diabetics.
8.1.2. Blood pressure control
The current British Hypertension Society guidelines define hypertension as systolic blood
pressure ≥ 140mmHg and/ or diastolic blood pressure ≥ to 90mmHg [133]. In diabetes treatment
targets should be systolic level <130 mm Hg and diastolic <80 mm Hg. Lower levels may be
required for younger patients with Type 1 diabetes and microvascular complications. In this
group of patients treatment with ACE inhibitors resulted in a 50% reduction in the progression
of retinopathy and progression to proliferative diabetic retinopathy by 80% in the EURODIAB
Controlled Trial of Lisinopril in Insulin Dependent Diabetes Mellitus (EUCLID) trial [134].
Type 2 diabetics in the UKPDS study showed that tight BP control prevented the progression
of retinopathy. The beneficial effects of anti-hypertensive medication are immediate on
commencing treatment, however the effects wear off as soon as control is lost. It is imperative
therefore that blood pressure is measured at every clinical visit.
8.1.3. Lipid control
Observational studies suggest that dyslipideamia increases the risk of diabetic retinopathy
particularly diabetic macula oedema[135, 136].
In the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study [137], type 2
diabetic patients were treated with fenofibrate. Those patients treated with fenofibrate were
less likely than controls to need laser treatment (5.2% vs 3.6%, p<0.001).
8.1.4. Cigarette smoking
In type 1 diabetes smoking increases the risk of diabetic retinopathy, nephropathy and
neuropathy. Discontinuation of smoking is recommended for reducing the development of
other complications of diabetes especially cardiovascular disease.
8.1.5. Management of macula oedema
Diabetic macula oedema is the most common cause for visual impairment particularly in type
2 diabetic patients. The management of clinically significant macula oedema depends on
whether there is evidence of central macular thickening or vitreomacular traction. There are a
wide variety of new treatments available currently some licensed and some unlicensed. A
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summary guideline as to the use of these treatments and their indications are summarized in
Table 3.
Is the centre
involved? Visual Acuity
Phakic/
Pseudophakic
OCT- central
retinal thickness Treatment options
No Either Focal/Grid laser
Yes Normal or "/>78 letters Either Focal/Grid laser/Observation iflesions too close to fovea
Yes 78-24 letters orsymptomatic Phakic ≥ 250 microns
Intravitreal anti- VEGF with or
without laser. If unresponsive
consider flucinolone implant.
Yes 78-24 letters Pseudophakic ≥250 microns
Intravitreal anti- VEGF or
intravitreal triamcinolone
preservative free with or without
laser. If unresponsive consider
flucinolone implant.
Yes <24 letters Pseudophakic ≥250 microns
Observation especially if long
standing or unrepsonsive to
laser. Consider macula
ischaemia. Otherwise consider
anti-VEGF or intravitreal steroid
Yes Either Vitreomaculartraction
Consider vitrectomy with or
without adjunctive intravitreal
anti-VEGF or steroid treatment
Management of diabetic maculopathy. Adapted from Royal College of Ophthalmologists. Diabetic Retinopathy Guide‐
lines December 2012 (19)
Table 3. Table for management of CMO in Royal College of Ophthalmology
8.1.6. Laser photocoagulation
There is a strong evidence from the Early treatment of Diabetic retinopathy Study that focal
and grid laser photocoagulation for clinically significant macula oedema reduces the chance
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of moderate vision loss (3 ETDRS lines) by 50%, (from 24% for the control group to 12% for
the treatment group) at 3 years [19].
It is important to perform a fundus fluorescein angiography prior to treatment to delineate the
area of leakage and identify areas of macula ischaemia. In focal maculopathy, focal laser
treatment burns are applied directly to microaneurysms and and microvascular lesions in the
centre of rings of exudates located 500-3000 microns from the centre of the macula. The spot
size is 50-100 microns and exposure time 0.1 second with sufficient power to obtain gentle
whitening or darkening of the microaneurysm. In macula grid laser treatment burns are
applied to areas of diffuse retinal thickening more than 500 microns from the centre of the
macula and 500 microns from the temporal margin of the optic disc. The spot size is 100 microns
and exposure time 0.1 sec giving a very light intensity burn. Treatment should be lighter if
significant macular ischaemia is present.
In addition to argon laser treatment two other forms of laser treatment frequency-doubled
Nd:YAG laser and micropulse laser are available for the treatment of macula oedema which
reduce the degree of retinal collateral thermal damage. The ‘Pattern Scan Laser’ (Pascal) uses
frequency –doubled micropulse YAG in single shot mode or in a predetermined array of upto
56 shots applied in less than a second. This not only reduces the potential destructive retinal
effect but allows the operator to apply multiple spots simultaneously with a single foot pedal
depression.
Using a micropulse mode laser, energy is delivered with a train of repetitive short pulses,
micropulse power as low as 10%-25% of the visible threshold power has been demonstrated
to be sufficient to show RPE-confined photothermal effect.
8.1.7. Intravitreal anti-vascular endothelial growth factors (anti-VEGF) agents
Multiple studies have demonstrated the benefit of the anti-VEGF agents including pegaptanib,
ranibizumab and bevacizumab for the treatment of central involving diabetic macula oedema.
A large multicenter trial DRCRnet(The Diabetic Retinopathy Research Network Laser-
Ranibizumab-Triamcinolone Study)[138] showed that intravitreal injection of 0.5mg ranibi‐
zumab initially given monthly for 3 months with prompt or deferred (≥ 24 weeks) macular
laser had significantly superior visual and OCT outcomes to laser alone in eyes with diabetic
macula oedema involving the fovea.
The READ-2 (Ranibizumab for oedema of macula in diabetes) [139], RESOLVE (Safety and
Efficacy of Ranibizumab in diabetic macula oedema) [140], RESTORE (Ranibizumab mono‐
therapy or combined with laser versus laser monotherapy for diabetic macula oedema) [141],
and BOLT (Bevacizumab or Laser therapy)[142] studies have all demonstrated that centre-
involving macula oedema should be considered for treatment with a VEGF inhibitor alone or
in conjunction with focal laser.
Ranibizumab is now licensed for use in the European Union for the treatment of centre
involving diabetic macula oedema and NICE have approved its use in patients with a central
retinal thickness of ≥ 400 microns on OCT.
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The Da VINCI trial (14) evaluated the safety and efficacy of intravitreal aflibercept for diabetic
macula oedema. Four treatment regimes were studied versus laser positive results have been
reported at 1 year with aflibercept. The maximum letters gain with aflibercept has been 13.1
letters vs 1.3 letters in the laser treated group. It is expected that this treatment will be licensed
for Diabetic retinopathy in 2014.
8.1.8. Intraocular steroid
DRCRnet[138] study found that in pseudophakic eyes intravitreal triamcinolone injection
followed by prompt laser may be as effective as ranibizumab at improving vision and reducing
retinal thickening. However, there was a significant risk of an elevation of intraocular pressure.
No corresponding visual benefit above laser was shown for phakic eyes, which also has had
a substantially increased rate of cataract surgery by two years.
Flucinolone acetonide is a non-biodegradable intravitreal insert (Illuvein) with sustained
release flucinolone and is licensed for use in the UK for chronic diabetic macula oedema
unresponsive to other treatment options but it is not yet approved by NICE. Studies have
shown that IIluvein can provide treatment benefit for three years-the best corrected visual
acuity showed an improvement of 15 or more letters in 28.7% of the low dose group vs 16.2%
in controls[144]. The longer acting nature is advantageous in that the patient would not require
monthly injections as is the case with the anti-VEGFs. However there is a greater chance of
development of cataract and raised intraocular pressure.
8.1.9. Pars plana vitrectomy
A vitrectomy with or without ILM peel may be indicated when macular oedema with or
without ischaemia is associated with tangential traction from a thickened and taut posterior
hyaloid. Often the oedema is unresponsive to laser and optical coherence tomography
scanning may show vitreomacular traction.
8.2. Management of Proliferative Diabetic Retinopathy (PDR)
8.2.1. Pan retinal photocoagulation
This is indicated in the presence of new vessels at the optic disc, iris, angle or elsewhere with
or without associated vitreous haemorrhage. Where possible PRP laser treatment should be
initiated on the same day and maximum within 2 weeks.
PRP laser treatment should be applied as far peripheral as possible using the laser contact lens
up to the ora serrata as the main areas of retinal ischaemia exist in the far peripheral retina.
The laser settings depend on the type of lens that is used. With a Goldmann lens the spot size
is set at 200-500 microns but with a panfundsocopic-type lens it is set at 100-300 microns. The
burn duration should be set between 0.05-0.1 seconds and the power should be sufficient to
produce only a light intensity burn.
Initial treatment involves 1500-2000 burns in a scatter pattern extending from the posterior
fundus to cover the peripheral retina in one or more sessions. PRP completed in one session
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carries a higher risk of complications and therefore treatment should be staggered. The number
of burns recommended is dependent on the stage of PDR ; early PDR 1200-1800 burns, in
moderate PDR 2000-2500 burns and in severe PDR 3000 burns.
The Diabetic Retinopathy Study[145] found that the risk of severe visual loss (5/200) was
reduced by 50% in the “high-risk” group treated with PRP. Patients with early proliferative
diabetic retinopathy were evaluated in the ETDRS study. In this group PRP decreased the risk
of patients developing high risk characteristics by 50%.
The main side effects of PRP laser treatment is the progression or development of diabetic
macula oedema, vitreous haemorrhage, tractional retinal detachment, loss of night vision and
constricted peripheral visual fields. Vision loss within 6 weeks of treatment has also been
reported in 10-23% of patients compared with 6 % of controls.
8.2.2. VEGF inhibitors
VEGF is implicated in the development of retinal neovascularization. Intravitreal anti-VEGF
is likely to have an increasing role in the treatment of proliferative diabetic retinopathy,
probably as an adjunct to laser. Anti-VEGFS can also be used in the setting of proliferative
diabetic retinopathy and vitreous haemorrhage to facilitate sufficient clearing of the haemor‐
rhage and allow administration of PRP.
8.2.3. Vitrectomy
Indications for pars plana vitrectomy are listed below:
1. Severe persistent vitreous haemorrhage
The surgical goal is to remove the vitreous opacity through a 3 port pars plana vitrectomy. The
posterior hyaloid face should be removed as this provides a scaffold for fibrovascular prolif‐
eration. The Diabetic Retinopathy Vitrectomy Study (DRVS)[146] 2 year results demonstrate
that in eyes with central vitreous haemorrhage that reduced acuity to 50/200 or less for at least
a month, vitrectomy carried out before 6 months resulted in an increase in the number of eyes
achieving 20/40 or better acuity compared with eyes in which vitrectomy was deferred to a
year. Patients with vitreous haemorrhage should be monitored weekly to ensure early
detection of retinal detachment.
Type 2 diabetics are less likely to have severe proliferative retinopathy, however there is a
growing trend to operate within 3 months as opposed to deferred surgery in both type 1 and
type 2 diabetics.
2. Tractional retinal detachment
Tractional retinal detachment recently involving or imminently threatening the fovea is
another common indication for surgery. Progressive traction produces a retinal break usually
posterior to the equator and near an area of fibrous proliferation. These detachments progress
quickly and usually result in a worse prognosis. Fibrovascular tissue proliferation and
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contraction attached to multiple retinal foci results in macular distortion (heterotropia) or
tractional detachment.
3. Combined tractional/rhegmatogenous retinal detachments
These should be treated urgently even if the macula is not involved as subretinal fluid is likely
to spread quickly and involve the macula.
4. Premacular subhyaloid haemorrhage
If dense and persistent should be considered for vitrectomy because if untreated the internal
limiting membrane or posterior hyaloid face may serve as a scaffold for subsequent fibrovas‐
cular proliferation and consequent tractional macular detachment or macular epiretinal
membrane formation.
5. Ghost Cell Glaucoma
Vitrectomy has also been shown in case series to be of benefit when there is ghost cell glaucoma
[147]. Raised intraocular pressure may be caused by partially lysed red cells (erthyroclasts)
particularly in eyes with a disrupted anterior hyaloid face after previous vitrectomy for
vitreous haemorrhage or in aphakic eyes with vitreous haemorrhage.
8.2.4. Management of Rubeosis Iridis
This occurs in eyes with severe retinal ischaemia or persistent retinal detachment. New vessels
on the iris should be treated with PRP laser to induce regression of these vessels.
Current practice for new vessels on the iris and at the angle includes full PRP and an intravitreal
anti-VEGF injection to prevent the progression to neovascular glaucoma. Treatment for
neovascular glaucoma include cycloablative procedures, trabeculectomy with anti-prolifera‐
tives and implantation of a drainage tube.
Eyes that have become blind from neovascular glaucoma should be kept comfortable with
topical steroids and atropine.
9. Conclusion
The global pandemic of diabetes means that retinopathy and associated visual difficulties
are  an ongoing problem.  Further  research is  needed into  the  impact  of  diabetes  on the
neurovascular  unit  to  facilitate  greater  understanding  of  pathophysiology.  Improved
screening and outcomes of  treatment  in  developed countries  mean vision can be  main‐
tained for longer. Ideally however, socioeconomic barriers need to be overcome to facilitate
translational research to all parts of the world, including poorer areas. Most importantly,
education on risk factors and tight glycaemic control are paramount to help prevent visual
problems occurring.
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